28391978|t|Recombinant protein transduction domain - Cu/Zn superoxide dismutase alleviates bone cancer pain via peroxiredoxin 4 modulation and antioxidation
28391978|a|Bone cancer pain (BCP) is a serious chronic clinical condition and reactive oxygen species (ROS) were considered to be involved in its development and persistency. Normally, superoxide dismutase (SOD) converts superoxide anions to hydrogen peroxide (H2O2) and H2O2 is then naturalized to be water by peroxiredoxin 4. We reported previously that recombinant protein transduction domain (PTD)- Cu/Zn SOD effectively scavenged excessive ROS and prevented cardiomyocytes from hypoxia-reoxygenation damage. However, whether PTD - Cu/Zn SOD would prevent BCP development is unknown. In the current study, we found that an implanted carcinoma in the rat tibia induced remarkable hyperalgesia, increased H2O2 levels and decreased SOD and peroxiredoxin 4 levels. After administration of recombinant PTD - Cu/Zn SOD to these tumor-burden rats, their hyperalgesia was significantly attenuated and peroxiredoxin 4 expression was significantly increased. In addition, an increased expression of N-methyl-d-aspartic acid (NMDA) receptors and a decreased expression of γ-aminobutyric acid (GABA) receptors in this cancer pain were prevented by PTD - Cu/Zn SOD administration or peroxiredoxin 4 overexpression. Our data suggested that reactive oxygen species, at least in part, play a role in cancer metastatic pain development and persistency which can be attenuated by the adminstration of recombinant PTD - Cu/Zn SOD via the peroxiredoxin 4 modulation from oxidative stress.
28391978	0	11	Recombinant	T116	C0034861
28391978	12	39	protein transduction domain	T087	C1514562
28391978	42	68	Cu/Zn superoxide dismutase	T116,T126	C0010461
28391978	69	79	alleviates	T080	C0392756
28391978	80	91	bone cancer	T191	C0279530
28391978	92	96	pain	T184	C0596240
28391978	101	116	peroxiredoxin 4	T116,T126	C0914290
28391978	117	127	modulation	T044	C1148560
28391978	132	145	antioxidation	T044	C1148560
28391978	146	157	Bone cancer	T191	C0279530
28391978	158	162	pain	T184	C0596240
28391978	164	167	BCP	T184	C0596240
28391978	174	181	serious	T080	C0205404
28391978	182	189	chronic	T079	C0205191
28391978	190	208	clinical condition	T080	C0348080
28391978	213	236	reactive oxygen species	T123,T196	C0162772
28391978	238	241	ROS	T123,T196	C0162772
28391978	248	258	considered	T078	C0750591
28391978	265	273	involved	T169	C1314939
28391978	281	292	development	T169	C1527148
28391978	297	308	persistency	T079	C0205322
28391978	310	318	Normally	T080	C0205307
28391978	320	340	superoxide dismutase	T116,T121,T126	C0038838
28391978	342	345	SOD	T116,T121,T126	C0038838
28391978	356	373	superoxide anions	T196	C0038836
28391978	377	394	hydrogen peroxide	T121,T130,T197	C0020281
28391978	396	400	H2O2	T121,T130,T197	C0020281
28391978	406	410	H2O2	T121,T130,T197	C0020281
28391978	437	442	water	T121,T197	C0043047
28391978	446	461	peroxiredoxin 4	T116,T126	C0914290
28391978	466	474	reported	T170	C0684224
28391978	491	502	recombinant	T116	C0034861
28391978	503	530	protein transduction domain	T087	C1514562
28391978	532	535	PTD	T087	C1514562
28391978	538	547	Cu/Zn SOD	T116,T126	C0010461
28391978	548	559	effectively	T080	C1704419
28391978	560	569	scavenged	T044	C1148560
28391978	570	579	excessive	T080	C0442802
28391978	580	583	ROS	T123,T196	C0162772
28391978	588	597	prevented	T169	C1292733
28391978	598	612	cardiomyocytes	T025	C0225828
28391978	618	639	hypoxia-reoxygenation	T169	C0542341
28391978	640	646	damage	T169	C1883709
28391978	665	668	PTD	T087	C1514562
28391978	671	680	Cu/Zn SOD	T116,T126	C0010461
28391978	687	694	prevent	T169	C1292733
28391978	695	698	BCP	T184	C0596240
28391978	699	710	development	T169	C1527148
28391978	714	721	unknown	T080	C0439673
28391978	730	737	current	T079	C0521116
28391978	738	743	study	T062	C0681814
28391978	748	753	found	T033	C0150312
28391978	762	771	implanted	T074	C0021102
28391978	772	781	carcinoma	T191	C0007097
28391978	789	792	rat	T015	C0034721
28391978	793	798	tibia	T023	C0040184
28391978	799	806	induced	T169	C0205263
28391978	818	830	hyperalgesia	T184	C0020429
28391978	832	841	increased	T081	C0205217
28391978	842	846	H2O2	T121,T130,T197	C0020281
28391978	847	853	levels	T080	C0441889
28391978	858	867	decreased	T081	C0205216
28391978	868	871	SOD	T116,T121,T126	C0038838
28391978	876	891	peroxiredoxin 4	T116,T126	C0914290
28391978	892	898	levels	T080	C0441889
28391978	906	920	administration	T169	C1521801
28391978	924	935	recombinant	T116	C0034861
28391978	936	939	PTD	T087	C1514562
28391978	942	951	Cu/Zn SOD	T116,T126	C0010461
28391978	961	973	tumor-burden	T081	C1516167
28391978	974	978	rats	T015	C0034721
28391978	986	998	hyperalgesia	T184	C0020429
28391978	1003	1016	significantly	T078	C0750502
28391978	1017	1027	attenuated	T052	C0599946
28391978	1032	1047	peroxiredoxin 4	T116,T126	C0914290
28391978	1048	1058	expression	T045	C1171362
28391978	1063	1086	significantly increased	T081	C4055637
28391978	1088	1099	In addition	T169	C0332287
28391978	1104	1113	increased	T081	C0205217
28391978	1114	1124	expression	T045	C0597360
28391978	1128	1169	N-methyl-d-aspartic acid (NMDA) receptors	T116,T192	C0080093
28391978	1176	1185	decreased	T081	C0205216
28391978	1186	1196	expression	T045	C0597360
28391978	1200	1236	γ-aminobutyric acid (GABA) receptors	T116,T192	C0206518
28391978	1245	1256	cancer pain	T184	C0596240
28391978	1262	1271	prevented	T169	C1292733
28391978	1275	1278	PTD	T087	C1514562
28391978	1281	1290	Cu/Zn SOD	T116,T126	C0010461
28391978	1291	1305	administration	T169	C1521801
28391978	1309	1324	peroxiredoxin 4	T116,T126	C0914290
28391978	1325	1339	overexpression	T045	C1514559
28391978	1345	1349	data	T078	C1511726
28391978	1350	1359	suggested	T078	C1705535
28391978	1365	1388	reactive oxygen species	T123,T196	C0162772
28391978	1415	1419	role	T077	C1705810
28391978	1423	1440	cancer metastatic	T191	C0027627
28391978	1441	1445	pain	T184	C0596240
28391978	1446	1457	development	T169	C1527148
28391978	1462	1473	persistency	T079	C0205322
28391978	1487	1500	attenuated by	T080	C0332161
28391978	1505	1518	adminstration	T169	C1521801
28391978	1522	1537	recombinant PTD	T116	C0034861
28391978	1540	1549	Cu/Zn SOD	T116,T126	C0010461
28391978	1558	1573	peroxiredoxin 4	T116,T126	C0914290
28391978	1574	1584	modulation	T044	C1148560
28391978	1590	1606	oxidative stress	T049	C0242606